Editorial: We may need large trials to find treatments for neurodegenerative diseases

Abstract

Keywords

Alzheimer’s disease ALS Parkinson’s disease clinical trials sample size

Get full access to this article

View all access options for this article.

References

Brookmeyer

Abdalla

. Design and sample size considerations for Alzheimer’s disease prevention using multistate models. Clin Trials, in press.

Steering Committee of the Physicians Health Study Research Group. Final report on the aspirin component of the ongoing physicians’ health study. N Engl J Med 1989; 321(3): 129–135.

Meldrum

A ‘calculated risk’: the Salk polio vaccine field trials of 1954. BMJ 1998; 317(7167): 1233–1236.

Cummings

Doody

Clark

Disease-modifying therapies for Alzheimer disease challenges to early intervention. Neurology 2007; 69(16): 1622–1634.

Benatar

Wuu

Presymptomatic studies in ALS: rationale, challenges, and approach. Neurology 2012; 79(16): 1732–1739.

Noyce

Lees

Schrag

AE.

The prediagnostic phase of Parkinson’s disease. J Neurol Neurosurg Psychiatry 2016; 87(8): 871–878.

Burns

Iliffe

Alzheimer’s disease. BMJ 2009; 338: b158.

Meek

McKeithan

Schumock

GT.

Economic considerations in Alzheimer’s disease. Pharmacotherapy 1998; 18(2 Pt. 2): 68–73.

Benatar

Polak

Kaplan

, et al. Preventing familial amyotrophic lateral sclerosis: is a clinical trial feasible? J Neurol Sci 2006; 251(1–2): 3–9.